JAK3 - Janus kinase 3 Gene
Species: Macaca fascicularis
Gene Type: protein coding
Gene ID: 102134669
About JAK3
Primary_assembly 19: 17,776,534-17,799,029 reverse strand.Macaca_fascicularis_6.0:CM021957.1
This gene has 4 transcripts (splice variants), 103 orthologues and 30 paralogues.
JAK3 Products (6)
| mRNA | Protein | Name |
|---|---|---|
| XM_015440242.2 | XP_015295728.2 | tyrosine-protein kinase JAK3 isoform X3 |
| XM_045380804.1 | XP_045236739.1 | tyrosine-protein kinase JAK3 isoform X2 |
| XM_005588397.3 | XP_005588454.2 | tyrosine-protein kinase JAK3 isoform X1 |
| XM_045380805.1 | XP_045236740.1 | tyrosine-protein kinase JAK3 isoform X2 |
| XM_045380803.1 | XP_045236738.1 | tyrosine-protein kinase JAK3 isoform X2 |
| XM_045380807.1 | XP_045236742.1 | tyrosine-protein kinase JAK3 isoform X4 |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
tyrosine-protein kinase JAK3 |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(23)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-50856 | Ruxolitinib | Inhibitor | 99.99% | Yes |
| HY-40354 | Tofacitinib | Inhibitor | 99.99% | Yes |
| HY-19569 | Upadacitinib | Inhibitor | 99.98% | Yes |
| HY-15315 | Baricitinib | Inhibitor | 99.97% | Yes |
| HY-50858 | Ruxolitinib phosphate | Inhibitor | 99.97% | Yes |
| HY-40354A | Tofacitinib citrate | Inhibitor | 99.94% | Yes |
| HY-100754 | Ritlecitinib | Inhibitor | 99.80% | Yes |
| HY-16379 | Pacritinib | Inhibitor | 99.93% | Yes |
| HY-18300 | Filgotinib | Inhibitor | 99.77% | Yes |
| HY-19568 | Peficitinib | Inhibitor | 99.43% | Yes |
| HY-15315A | Baricitinib phosphate | Inhibitor | 99.97% | Yes |
| HY-109053 | Delgocitinib | Inhibitor | 99.61% | Unkown |
| HY-13577 | Oclacitinib | Inhibitor | 99.03% | Unkown |
| HY-13577A | Oclacitinib monomaleate | Inhibitor | 99.87% | Unkown |
| HY-18300A | Filgotinib maleate | Inhibitor | 99.88% | Yes |
| HY-100754C | Ritlecitinib tosylate | Inhibitor | 99.65% | Yes |
| HY-112961 | Patiromer | Inhibitor | 95.0% | Unkown |
| HY-50859 | Ruxolitinib sulfate | Inhibitor | / | Unkown |
| HY-19569A | Upadacitinib tartrate tetrahydrate | Inhibitor | / | Unkown |
| HY-19568A | Peficitinib hydrobromide | Inhibitor | / | Unkown |
| HY-100754A | Ritlecitinib malonate | Inhibitor | / | Unkown |
| HY-16379A | Pacritinib hydrochloride | Inhibitor | / | Unkown |
| HY-19568B | Peficitinib hydrochloride | Inhibitor | / | Unkown |
Clinical Phase
Bioactive Molecules
(21)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-10961 | Momelotinib | Inhibitor | 98.93% | Phase 3 |
| HY-112708 | Brepocitinib | Inhibitor | 99.97% | Phase 3 |
| HY-50514 | AT9283 | Inhibitor | 99.67% | Phase 3 |
| HY-15999 | Cerdulatinib | Inhibitor | 99.06% | Phase 3 |
| HY-12469 | Decernotinib | Inhibitor | 99.91% | Phase 3 |
| HY-10962 | Momelotinib sulfate | Inhibitor | 98.63% | Phase 3 |
| HY-112724 | Ivarmacitinib | Inhibitor | 99.62% | Phase 3 |
| HY-13775 | XL019 | Inhibitor | 99.65% | Phase 3 |
| HY-15999A | Cerdulatinib hydrochloride | Inhibitor | 98.96% | Phase 3 |
| HY-10963 | Momelotinib mesylate | Inhibitor | / | Phase 3 |
| HY-13034 | Gandotinib | Inhibitor | 99.86% | Phase 2 |
| HY-130247 | Flonoltinib | Inhibitor | 99.48% | Phase 2 |
| HY-15270 | BMS-911543 | Inhibitor | 98.23% | Phase 2 |
| HY-19631A | Ilginatinib | Inhibitor | 99.81% | Phase 2 |
| HY-156961 | Cadefrecitinib | Inhibitor | 99.81% | Phase 2 |
| HY-112708A | Brepocitinib P-Tosylate | Inhibitor | 99.99% | Phase 2 |
| HY-19631B | Ilginatinib hydrochloride | Inhibitor | 98.92% | Phase 2 |
| HY-19631 | Ilginatinib maleate | Inhibitor | 99.33% | Phase 2 |
| HY-130247A | Flonoltinib TFA | Inhibitor | 98.94% | Phase 2 |
| HY-10058 | AT9283 lactic acid | Inhibitor | / | Phase 2 |
| HY-101024 | PF-06263276 | Inhibitor | ≥99.0% | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(97)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-14435 | Pyridone 6 | Inhibitor | 98.20% | Unkown |
| HY-131140 | BD750 | Inhibitor | 99.02% | Unkown |
| HY-15508 | JANEX-1 | Inhibitor | 99.63% | Unkown |
| HY-15343 | CEP-33779 | Inhibitor | 99.23% | Unkown |
| HY-145551 | Atinvicitinib | Inhibitor | 98.62% | Unkown |
| HY-145696 | SJ10542 | Inhibitor | 99.32% | Unkown |
| HY-10411 | AZ960 | Inhibitor | 97.08% | Unkown |
| HY-14722 | NVP-BSK805 | Inhibitor | 99.30% | Unkown |
| HY-10410 | TG101209 | Inhibitor | 98.81% | Unkown |
| HY-102046 | FM-381 | Inhibitor | 98.08% | Unkown |
| HY-100895 | SAR-20347 | Inhibitor | 97.27% | Unkown |
| HY-108264 | TCS 21311 | Inhibitor | 99.49% | Unkown |
| HY-151262 | JAK-IN-23 | Inhibitor | 98.88% | Unkown |
| HY-12589 | ZM39923 hydrochloride | Inhibitor | 99.84% | Unkown |
| HY-18313 | S6K1-IN-1 | Inhibitor | 99.71% | Unkown |
| HY-11067 | WHI-P97 | Inhibitor | 99.16% | Unkown |
| HY-153701S | Envudeucitinibum | Inhibitor | 99.56% | Unkown |
| HY-101976 | JAK3-IN-6 | Inhibitor | 99.48% | Unkown |
| HY-14722A | NVP-BSK805 dihydrochloride | Inhibitor | 99.36% | Unkown |
| HY-13895 | WHI-P154 | Inhibitor | 98.77% | Unkown |
| HY-19544 | JAK3-IN-1 | Inhibitor | 99.31% | Unkown |
| HY-174280 | Modzatinib | Inhibitor | / | Unkown |
| HY-131906 | JAK2-IN-7 | Inhibitor | 98.31% | Unkown |
| HY-150720 | TYK2-IN-12 | Inhibitor | 98.81% | Unkown |
| HY-150023 | BI-1622 | Inhibitor | 98.02% | Unkown |
| HY-153440 | Methyl 6-(1-(4-methoxybenzyl)-1H-pyrazol-4-yl)-4-oxo-4,5-dihydropyrazolo[1,5-a]pyrazine-2-carboxylate | Inhibitor | 98.01% | Unkown |
| HY-120469 | 2,6-Dichloro-N-(2-(cyclopropanecarboxamido)pyridin-4-yl)benzamide | Inhibitor | 99.80% | Unkown |
| HY-139423 | JAK1-IN-8 | Inhibitor | 95.0% | Unkown |
| HY-143444 | JAK-IN-20 | Inhibitor | 99.63% | Unkown |
| HY-136336 | Tofacitinib metabolite-1 | Inhibitor | 99.59% | Unkown |
| HY-111750 | JAK-IN-3 | Inhibitor | 98.92% | Unkown |
| HY-126141 | JAK/HDAC-IN-1 | Inhibitor | 98.63% | Unkown |
| HY-13961 | GLPG0634 analog | Inhibitor | 98.07% | Unkown |
| HY-100754B | (2R,5S)-Ritlecitinib | Inhibitor | 99.77% | Unkown |
| HY-152080 | Blovacitinib | Inhibitor | 99.71% | Unkown |
| HY-100849 | JAK 3i | Inhibitor | 99.81% | Unkown |
| HY-13450 | ZM 449829 | Inhibitor | 99.73% | Unkown |
| HY-159536 | Frevecitinib | Inhibitor | 99.42% | Unkown |
| HY-131014 | FM-479 | 99.2% | Unkown | |
| HY-170772 | Dual Cathepsin L/JAK-IN-1 | Inhibitor | 98.47% | Unkown |
| HY-161618 | MJ04 | Inhibitor | 98.08% | Unkown |
| HY-119935 | JAK3 covalent inhibitor-1 | Inhibitor | / | Unkown |
| HY-147754 | JAK3/BTK-IN-6 | Inhibitor | / | Unkown |
| HY-155951 | JAK3-IN-14 | Inhibitor | 99.32% | Unkown |
| HY-178282 | JAK1-IN-19 | Inhibitor | / | Unkown |
| HY-174430 | WWQ-131 | Inhibitor | / | Unkown |
| HY-N14094 | Tubulosine | Inhibitor | / | Unkown |
| HY-120457 | WYE-151650 | Inhibitor | / | Unkown |
| HY-151256 | JAK-2/3-IN-2 | Inhibitor | / | Unkown |
| HY-178448 | EGFR-IN-178 | Inhibitor | / | Unkown |
| HY-181663 | PJ27 | Inhibitor | / | Unkown |
| HY-182314 | JAK3-IN-20 | Inhibitor | / | Unkown |
| HY-170723 | JAK-IN-39 | Inhibitor | / | Unkown |
| HY-147975 | JAK3-IN-12 | Inhibitor | / | Unkown |
| HY-168718 | FAK-IN-22 | Inhibitor | / | Unkown |
| HY-151285 | JAK-2/3-IN-3 | Inhibitor | / | Unkown |
| HY-108342 | PF-00956980 | Inhibitor | / | Unkown |
| HY-124657 | PRN-371 | Inhibitor | / | Unkown |
| HY-178755 | DEL1187-126-5-80 | Inhibitor | / | Unkown |
| HY-133747 | JAK3-IN-9 | Inhibitor | / | Unkown |
| HY-147742 | Thi-DPPY | Inhibitor | / | Unkown |
| HY-176793 | JAK1-IN-18 | Inhibitor | / | Unkown |
| HY-151258 | TK4g | Inhibitor | / | Unkown |
| HY-147741 | DPPY | Inhibitor | / | Unkown |
| HY-174999 | JAK3-IN-18 | Inhibitor | / | Unkown |
| HY-149283 | JAK/HDAC-IN-2 | Inhibitor | / | Unkown |
| HY-115438 | AUH-6-96 | Inhibitor | / | Unkown |
| HY-18949 | JI6 | Inhibitor | / | Unkown |
| HY-138222 | JANEX-1 hydrochloride | Inhibitor | / | Unkown |
| HY-178763 | DEL1187-126-28-16 | Inhibitor | / | Unkown |
| HY-149296 | JAK1-IN-12 | Inhibitor | / | Unkown |
| HY-168269 | Tyk2-IN-20 | Inhibitor | / | Unkown |
| HY-175684 | JAK2-IN-14 | Inhibitor | / | Unkown |
| HY-10652 | JAK-2/3-IN-1 | Inhibitor | / | Unkown |
| HY-168339 | Tyk2-IN-22 | Inhibitor | / | Unkown |
| HY-154994 | JAK-IN-30 | Inhibitor | / | Unkown |
| HY-123099 | MS-1020 | Inhibitor | / | Unkown |
| HY-146727 | JAK3-IN-11 | Inhibitor | / | Unkown |
| HY-182361 | NUAK1-IN-3 | / | Unkown | |
| HY-161967 | JAK2/FLT3-IN-3 | Inhibitor | / | Unkown |
| HY-143885 | JAK1/TYK2-IN-3 | Inhibitor | / | Unkown |
| HY-164111 | JNK-IN-17 | Inhibitor | / | Unkown |
| HY-161354 | JAK3 covalent inhibitor-2 | Inhibitor | / | Unkown |
| HY-151259 | TK4b | Inhibitor | / | Unkown |
| HY-173601 | JAK3-IN-17 | Inhibitor | / | Unkown |
| HY-162862 | JAK-IN-38 | Inducer | / | Unkown |
| HY-123187 | AS2553627 | Inhibitor | / | Unkown |
| HY-161912 | 5TTU | Inhibitor | / | Unkown |
| HY-130247B | Flonoltinib monomaleate | Inhibitor | / | Unkown |
| HY-180512 | JAK3-IN-19 | Inhibitor | / | Unkown |
| HY-157121 | JAK-IN-34 | Inhibitor | / | Unkown |
| HY-162862 | JAK-IN-38 | Inhibitor | / | Unkown |
| HY-123939 | JAK1/3-IN-1 | Inhibitor | / | Unkown |
| HY-12589A | ZM39923 | Inhibitor | / | Unkown |
| HY-123625 | R-348 choline | Inhibitor | / | Unkown |
| HY-122101 | NSC114792 | Inhibitor | / | Unkown |
| HY-U00390 | JAK3-IN-7 | Inhibitor | / | Unkown |